甲磺酸阿帕替尼在多线治疗失败的晚期结肠癌中的近期临床疗效与安全性观察

临床肿瘤学杂志 ›› 2018, Vol. 23 ›› Issue (5): 453-457.

甲磺酸阿帕替尼在多线治疗失败的晚期结肠癌中的近期临床疗效与安全性观察

1 221003 江苏徐州徐州医科大学附属医院肿瘤内科 2 221004 徐州医科大学研究生学院 3 221008 徐州市中心医院肿瘤内科
4 221006 徐州矿务集团总医院肿瘤内科

收稿日期:2018-01-11 修回日期:2018-03-28 出版日期:2018-05-31 发布日期:2018-06-07

Observation of apatinib mesylate treatment on colon cancer failed in multi-line chemotherapy

Department of Oncology， Hospital Affiliated to Xuzhou Medical University， Xuzhou 221003，China

Received:2018-01-11 Revised:2018-03-28 Online:2018-05-31 Published:2018-06-07

摘要/Abstract

摘要： 目的探讨甲磺酸阿帕替尼在多线治疗失败的晚期结肠癌治疗中的疗效及不良反应。方法收集2016年6月至2017年12月31例多线治疗失败的晚期结肠癌患者，接受甲磺酸阿帕替尼单药（n=7）或联合化疗（n=24）治疗。阿帕替尼初始剂量为425 mg／d，联合化疗药物包括替吉奥、伊立替康或奥沙利铂。采用RECIST 1.1版标准和NCI CTC 3.0版标准分别评价近期疗效和不良反应，并观察全组患者的无进展生存期（PFS）。结果治疗4周后31例可评价疗效的患者中，获部分缓解（PR）5例、稳定（SD）18例、进展（PD）8例，有效率（RR）为16.1％（5／31），疾病控制率（DCR）为74.2％（23／31）。治疗8周后30例可评价疗效的患者中，获PR 3例、SD 18例、PD 9例，RR为10.0％（3／30），DCR为70.0％（21／30）。接受阿帕替尼单药或联合化疗近期疗效的差异无统计学意义（P＞0.05）。31例患者的中位PFS为3.5个月，不同性别、年龄、肿瘤原发部位、转移部位及是否联合化疗之间PFS的差异无统计学意义（P＞0.05）。不良反应主要为高血压、蛋白尿、手足综合征、肝功能异常、血液系统毒性和乏力，以1～2级为主。高血压及蛋白尿发生率较高，均为16.1％。结论甲磺酸阿帕替尼治疗多线治疗失败的晚期结肠癌的近期疗效显著，毒性可控，可作为多线治疗失败的晚期结肠癌患者的一种有效的治疗选择，以期延长患者的生存期。

关键词: 结肠癌, 甲磺酸阿帕替尼, 临床疗效, 安全性

Abstract: Objective To investigate the efficacy and safety of apatinib mesylate on advanced colon cancer failed in multi-line treatment. Methods From June 2016 to December 2017， 31 cases of advanced colon cancer failed in multi-line treatment received apatinib mesylate monotherapy （n=7） or in combination with chemotherapy （n=24） were enrolled in this study. The initial dose of apatinib was 425 mg／d. Chemotherapy drugs included S-1， oxaliplatin and irinotecan. Clinical efficacy and side effect were evaluated by RECIST1.1 criteria and NCI CTC 3.0 criteria， respectively. Progression-free survival （PFS） was also observed. Results After 4 weeks of apatinib treatment， among the 31 patients could be evaluated， partial remission （PR） was found in 5 cases， stable disease （SD） in 18 cases， and progression disease （PD） in 8 cases. The response rate was 16.1％（5／31）， and disease control rate was 74.2％（23／31）. After 8 weeks of apatinib treatment， among the 30 patients could be evaluated， PR was found in 3 cases， SD in 18 cases， and PD in 9 cases. The RR was 10.0％（3／30）， and DCR was 70.0％（21／30）. The short-term efficacy between those received apatinib monotherapy or in combination with chemotherapy had no differences （P＞0.05）. The median PFS of 31 patients was 3.5 months. There was no significant difference in PFS between different sex， age， primary site of tumor， metastatic site of tumor and whether in combination with chemotherapy （P＞0.05）. The main adverse reactions were hypertension， proteinuria， hand-foot syndrome， abnormal liver function， hematological toxicity and fatigue， mainly in grade 1-2. The incidence of hypertension and proteinuria （both 16.1％） was higher than other adverse reactions. Conclusion Apatinib mesylate for patients of advanced colon cancer failed in multi-line treatment is effective， and the adverse reactions are tolerable， which can be regarded as a choice for advanced colon cancer failed in multi-line treatment.

Key words: Colon cancer, Apatinib mesylate, Clinical efficacy, Safety

中图分类号:

R735.3+5

王珊珊, 汪海岩, 武斌, 赵利红, 李栋, 谢彦. 甲磺酸阿帕替尼在多线治疗失败的晚期结肠癌中的近期临床疗效与安全性观察[J]. 临床肿瘤学杂志, 2018, 23(5): 453-457.

WANG Shanshan, WANG Haiyan, WU Bin, ZHAO Lihong, LI Dong, XIE Yan. . Observation of apatinib mesylate treatment on colon cancer failed in multi-line chemotherapy[J]. Chinese Clinical Oncology, 2018, 23(5): 453-457.

参考文献

Metrics

Viewed

Full text

Abstract

Cited

Shared

Discussed

本文评价

推荐阅读 10

[1]	刘锦；李贵新；马传香. 恶性黑色素瘤腹腔转移１例[J]. 临床肿瘤学杂志, 2009, 14(1): 96 .
[2]	石　玮¹，华海清²，王兴华¹. 放疗对肠屏障功能的影响及研究进展[J]. 临床肿瘤学杂志, 2009, 14(1): 89 .
[3]	王杰军，李　睿. ＮＣＣＮ成人癌痛临床实践指南解读[J]. 临床肿瘤学杂志, 2009, 14(1): 80 .
[4]	崔传亮，迟志宏，袁香庆，斯　璐，盛锡楠，郭　军. 重组人血管内皮抑制素联合化疗一线治疗晚期黑色素瘤的Ⅱ期临床研究[J]. 临床肿瘤学杂志, 2009, 14(1): 74 .
[5]	高亚杰¹，关小倩¹，杨海林¹，张　阳²，欧阳学农³，杨建伟⁴，陈　焰⁵,徐建明⁶，赵宣良⁷，王宝成⁸，刘文超⁹，张贺龙¹⁰，南克俊¹¹，王湘辉¹² . 注射用左亚叶酸钙联合治疗晚期胃癌和结直肠癌的Ⅱ期临床研究[J]. 临床肿瘤学杂志, 2009, 14(1): 47 .
[6]	徐卫国¹，杨小青²，郝世柱¹，宋纪宁¹，张鹏东¹，胡潺潺¹，王文雅¹. 大肠癌组织中Ｎｅｕｒｏｐｉｌｉｎ-１的表达及其与肿瘤血管生成的相关性研究[J]. 临床肿瘤学杂志, 2009, 14(1): 29 .
[7]	许景艳¹，欧阳建^１，章宜芬²，周荣富¹，陈　兵¹，张启国¹，杨永公¹，邵小雁¹，徐　勇¹，关朝阳¹. 原发性肋骨血管肉瘤的诊治探讨[J]. 临床肿瘤学杂志, 2009, 14(1): 70 .
[8]	徐晓明¹，唐金海¹，刘万花²，郑凯尔²，秦建伟¹，赵祥生¹，张　彤³. 触诊阴性乳腺癌的定位方法与同期手术治疗[J]. 临床肿瘤学杂志, 2009, 14(1): 43 .
[9]	张艳玲，邹　岚，肖　红，黄海辉，谭崇富，阮志华，王　希，梁后杰，庞学利. 影像引导调强放射治疗鼻咽癌[J]. 临床肿瘤学杂志, 2009, 14(1): 51 .
[10]	翟云芝¹，陈振东²，秦凤展¹. Ｅｚｒｉｎ和ＡＫＴ２在大肠癌组织中的表达及其临床意义[J]. 临床肿瘤学杂志, 2009, 14(1): 25 .